PHK
ABUS icon

Point72 Hong Kong’s Arbutus Biopharma ABUS Stock Holding History

Point72 Hong Kong’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,188
Closed -$18K – 51
2022
Q3 		$18K Buy
9,188
+8,765
+2,072% +$20.6K ﹤0.01% 1630
2022
Q2 		$1K Buy
+423
New +$1.08K ﹤0.01% 1803

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Hong Kong's ABUS Position: Q4 2022 in Review

Point72 Hong Kong sold out of Arbutus Biopharma (ABUS) in Q4 2022, closing a stake of 9,188 shares — an estimated $18K sold.

Point72 Hong Kong first reported a position in ABUS in Q2 2022 and held it in 2 quarters. The position peaked at $18K in Q3 2022. 114 funds tracked by Wall St. Rank hold ABUS as of Q4 2022.

  • Point72 Hong Kong reported no remaining Arbutus Biopharma position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 9,188 Arbutus Biopharma shares in Q4 2022, an estimated $18K.
  • Point72 Hong Kong first reported a position in Arbutus Biopharma in Q2 2022 and held it in 2 quarters.
  • Point72 Hong Kong's Arbutus Biopharma position peaked at $18K in Q3 2022.
  • 114 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.